Get the Stockscreener App
1.95
3.94%
-0.08
Caribou Biosciences Inc stock is traded at $1.95, with a volume of 1.25M.
It is down -3.94% in the last 24 hours and up +56.00% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$2.03
Open:
$1.95
24h Volume:
1.25M
Relative Volume:
0.84
Market Cap:
$181.36M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.3356
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-14.47%
1M Performance:
+56.00%
6M Performance:
+36.36%
1Y Performance:
-12.95%
1-Day Range:
$1.86
$1.99
1-Week Range:
$1.86
$2.31
52-Week Range:
$0.66
$2.9995
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.95 | 188.80M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Is it the right time to buy Caribou Biosciences Inc. stockFinancial News Opportunities That Work - jammulinksnews.com
What makes Caribou Biosciences Inc. stock price move sharplyReal Time Watchlist With Proven Results - jammulinksnews.com
How Interest Rate Changes Impact Caribou Biosciences Inc. Stock PerformanceLong Hold Safe Return Strategy Reviewed - metal.it
Why Caribou Biosciences Inc. stock attracts strong analyst attentionTechnical Entry Strategy for Beginners Explained - beatles.ru
How many analysts rate Caribou Biosciences Inc. as a “Buy”Earnings Report Entry Points For Fast Growth - jammulinksnews.com
Why is Caribou Biosciences Inc. stock attracting strong analyst attentionHigh-velocity gains - jammulinksnews.com
What institutional investors are buying Caribou Biosciences Inc. stockMaximize returns with strategic trading plans - jammulinksnews.com
How does Caribou Biosciences Inc. compare to its industry peersRecord-breaking capital gains - jammulinksnews.com
What is Caribou Biosciences Inc. company’s growth strategyCapitalize on fast-growing investment opportunities - jammulinksnews.com
Published on: 2025-07-28 05:44:44 - jammulinksnews.com
Is Caribou Biosciences Inc. stock overvalued or undervaluedMaximize returns with data-driven strategies - jammulinksnews.com
What are the latest earnings results for Caribou Biosciences Inc.High-velocity capital appreciation - jammulinksnews.com
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
What analysts say about Caribou Biosciences Inc. stockSignificant capital appreciation - PrintWeekIndia
What risks could impact Caribou Biosciences Inc. stock performanceExtraordinary profit generation - jammulinksnews.com
What drives Caribou Biosciences Inc. stock priceFree High-Return Strategy Alerts - Autocar Professional
Following a 1.3% Decline Over Last Year, Recent Gains May Please Caribou Biosciences, Inc. (NASDAQ:CRBU) Institutional Owners - 富途牛牛
Caribou Biosciences Inc. Stock Analysis and ForecastRapid wealth multiplication - jammulinksnews.com
Is Caribou Biosciences Inc. a good long term investmentDynamic profit opportunities - Autocar Professional
Why Caribou Biosciences Inc. stock is on top investor watchlistsFast Gains With Reduced Risk - Newser
Citi reiterates Buy rating on Caribou Biosciences stock ahead of key data By Investing.com - Investing.com South Africa
Citi reiterates Buy rating on Caribou Biosciences stock ahead of key data - Investing.com India
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):